Keros Therapeutics, Inc.
KROS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001664710
In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Keros Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- +9 vs. Q2 2022
- Shares held
- 18.1M
- +718.8K (+4.1%) vs. Q2 2022
- Total value
- $680.1M
- +$200.4M (+41.8%) vs. Q2 2022
- New holders
- 24
- 39 more added
- Sold out
- 15
- 25 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KROS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 132 | $198.6M |
| Q1 2026 | 151 | $205.6M |
| Q4 2025 | 166 | $408.4M |
| Q3 2025 | 155 | $558.0M |
| Q2 2025 | 139 | $479.6M |
| Q1 2025 | 156 | $428.6M |
| Q4 2024 | 161 | $582.1M |
| Q3 2024 | 164 | $2.03B |
| Q2 2024 | 152 | $1.44B |
| Q1 2024 | 147 | $2.08B |
| Q4 2023 | 121 | $1.02B |
| Q3 2023 | 107 | $730.6M |
| Q2 2023 | 123 | $901.0M |
| Q1 2023 | 129 | $937.0M |
| Q4 2022 | 126 | $948.2M |
| Q3 2022 | 113 | $680.1M |
| Q2 2022 | 104 | $479.7M |
| Q1 2022 | 106 | $893.0M |
| Q4 2021 | 99 | $944.5M |
| Q3 2021 | 89 | $545.4M |
| Q2 2021 | 80 | $599.7M |
| Q1 2021 | 83 | $887.0M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Keros Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Woodline Partners LP | 342,493 | $12.9M | 0.19% | +342,493 | New |
| Candriam Luxembourg S.C.A. | 361,789 | $13.6M | 0.10% | 00.0% | Unchanged |
| Citadel Advisors LLC | 428,107 | $16.1M | 0.02% | +73,753+20.8% | Added |
| Franklin Resources Inc | 472,998 | $17.8M | 0.01% | +1180.0% | Added |
| Citigroup Inc | 476,123 | $17.9M | 0.03% | +13,753+3.0% | Added |
| First Light Asset Management, LLC | 598,213 | $22.5M | 2.28% | −1200.0% | Reduced |
| Nantahala Capital Management, LLC | 845,692 | $31.8M | 3.12% | −66,209−7.3% | Reduced |
| Vanguard Group Inc | 906,574 | $34.1M | 0.00% | +134,956+17.5% | Added |
| State Street Corp | 933,512 | $35.1M | 0.00% | −57,240−5.8% | Reduced |
| Alkeon Capital Management LLC | 1,208,822 | $45.5M | 0.31% | +32,389+2.8% | Added |
| BlackRock Inc. | 1,461,190 | $55.0M | 0.00% | +64,847+4.6% | Added |
| OrbiMed Advisors LLC | 1,679,417 | $63.2M | 1.26% | 00.0% | Unchanged |
| FMR LLC | 3,863,526 | $145.3M | 0.02% | +263,631+7.3% | Added |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −152,249−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −55,561−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −52,934−100.0% | Sold out |
| Altshuler Shaham Ltd | 0 | $0 | 0.00% | −34,074−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −33,356−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −21,056−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −16,623−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −14,341−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −11,613−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −10,020−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −6,364−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −1,006−100.0% | Sold out |
| High Net Worth Advisory Group LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −74−100.0% | Sold out |